Pharmaceuticals

I-Mab Strengthens Management Team Designed to Accelerate Global Pipeline Development and Transformation Towards Commercialization

-  New appointments as part of the Company's strategic development plans to accelerate transformation towards commercialization  -  Dr. Andrew Zhu, an internationally renowned oncologist, appointed as President and board director to lead the Company's R&D organization, focusing on global pipelin...

2021-12-20 21:00 2560

Everest Medicines and Providence Therapeutics announces that PTX-COVID19-B, a mRNA Vaccine for COVID-19, has received approval for inclusion in WHO Solidarity Trial Vaccines (STV) Program

SHANGHAI, Dec. 20, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) and Providence Therapeutics ("Providence") announced today that their COVID-19 vaccine, PTX-COVID19-B, has been recommended by an independent advisory group to be part of the WHO Solidarity Trial Vaccines ("STV") clinical t...

2021-12-20 20:55 4991

2021 Sustainability Report of Sai Life Sciences highlights the momentum gained in its Sustainability choices

* Report developed as per Global Reporting Initiative (GRI) standards * Extensively deals with the company's response to the Covid-19 pandemic HYDERABAD, India, Dec. 20, 2021 /PRNewswire/ -- Sai Life Sciences, a leading globalContract Research, Development & Manufacturing Organization

2021-12-20 19:16 1347

First Patient Dosed in Australia in ATG-101 First-in-Human Trial

SHANGHAI and HONG KONG, Dec. 20, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and onco...

2021-12-20 11:01 4868

First Patient Dosed in Australia in ATG-101 First-in-Human Trial

SHANGHAI AND HONG KONG, Dec. 19, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and onco...

2021-12-20 10:56 3485

Japan's MHLW Approves Booster Shot for SPIKEVAX®, Moderna's mRNA COVID-19 Vaccine

The SPIKEVAX® brand name was developed in partnership with Brand Institute, the global leader in pharmaceutical and healthcare-related name development MIAMI, Dec. 20, 2021 /PRNewswire/ -- Brand Institute is proud to announce its successful partnership with Moderna in naming their mRNA COVID-19 v...

2021-12-20 09:00 4532

Senhwa's Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Medulloblastoma

TAIPEI and SAN DIEGO, Dec. 17, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Des...

2021-12-17 20:00 3267

Westlake Omics Authorized as the Exclusive Distributor and Service Provider of Pressure BioSciences, Inc. in China

HANGZHOU, China, Dec. 17, 2021 /PRNewswire/ -- The Agreement signed by Westlake Omics (Hangzhou) Biotechnology Co., Ltd (hereinafter referred to as Westlake Omics) and Pressure BioSciences, Inc. (hereinafter referred to as PBI) on December 3, 2021 authorized Westlake Omics as the exclusive distrib...

2021-12-17 19:00 2365

Bioscience Animal Health Public Company Limited Accorded the International Innovation Awards 2021 for Angentex® COVID-19 qPCR Detection Kit

SINGAPORE, Dec. 17, 2021 /PRNewswire/ -- Enterprise Asia is pleased to honor 52 award recipients at the International Innovation Awards 2021. Spearheading the Innovation Revolution, the International Innovation Awards which aims to create an innovation ecosystem for enterprises is held annually t...

2021-12-17 18:24 2475

Study on Anti-aging with TCM Strides Forward

SHIJIAZHUANG, China, Dec. 17, 2021 /PRNewswire/ -- The opinions of experts on "Study on Anti-aging with Bazi Bushen Capsules Guided by Qi Collateral Theory" were released inShijiazhuang, Hebei on December 15. According to the opinions, the preliminary research of the project has created the theo...

2021-12-17 17:06 3504

Lipidor expands clinical program, announces investment in new drug development project against acne vulgaris

STOCKHOLM, Dec. 17, 2021 /PRNewswire/ -- Lipidor AB (publ) (Nasdaq First North: LIPI) today announces that it has initiated a preclinical program for a new drug candidate, AKP-08, focused on acne vulgaris (acne). The market for acne medicines amounts to about35 billion SEK per year, which togethe...

2021-12-17 16:10 2803

Transcenta Announces the Appointment of Daniel Weng as CFO

SUZHOU, China, Dec. 17, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces the appointment of Da...

2021-12-17 08:30 4721

Volition Executes its First Supply and Licensing Contract for its Nu.Q® Vet Cancer Screening Test in Asia

* SAGE Healthcare Private Limited appointed to serve as a non-exclusive licensee and distributor for Volition's Nu.Q® Vet Cancer Screening Test in centralized labs inSingapore, with launch planned in Singapore in the first quarter of 2022 followed by expansion in conjunction with SAGE Healthcar...

2021-12-16 21:00 3614

China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency

TAIZHOU, China, Dec. 16, 2021 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"),(NASDAQ: SXTC) announced today that on December 14, 2021, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC ("Nasdaq") notif...

2021-12-16 21:00 2464

Senhwa Clinical Data Abstract for Silmitasertib in Patients with Advanced Basal Cell Carcinoma Accepted for 2022 AAD Annual Meeting

TAIPEI and SAN DIEGO, Dec. 16, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that an abstract highlighting preliminary clinical data for their lead drug...

2021-12-16 20:00 2864

Bionomics Limited Announces Pricing of Initial Public Offering in the United States

ADELAIDE, Australia, Dec. 16, 2021 /PRNewswire/ -- Bionomics Limited (Bionomics orCompany), a clinical-stage biopharmaceutical company, today announced the pricing of its initial public offering inthe United States (the Offering) of 1,622,000 American Depositary Shares (ADSs), each representing 1...

2021-12-16 19:00 3377

BioWorld by Clarivate Identifies the Top Six Global Biopharmaceutical Stories and Trends of 2021

Advances in Alzheimer's, innovation in DNA vaccines, increased regulatory collaboration and the evolving impact of Artificial Intelligence, join Covid-19 as key stories and trends of 2021 LONDON, Dec. 16, 2021 /PRNewswire/ -- BioWorld published by Clarivate Plc  (NYSE:CLVT), a global leader in pr...

2021-12-16 16:14 2858

Debiopharm Further Explores the Potential of its Potent, Highly Selective WEE1 Inhibitor Debio 0123 In Phase 1 Cancer Study

Dose escalation, monotherapy trial launched to access the safety and preliminary anti-tumor activity of Debio 0123 in the treatment of advanced solid tumors LAUSANNE, Switzerland, Dec. 16, 2021 /PRNewswire/ -- Debiopharm ( www.debiopharm.com ), a Swiss biopharmaceutica...

2021-12-16 16:00 2560

PHASE 3 TRIAL OF SHR8058 EYE DROPS (PERFLUOROHEXYLOCTANE) CONDUCTED BY JIANGSU HENGRUI PHARMACEUTICALS IN THE PEOPLE'S REPUBLIC OF CHINA SHOWS STATISTICALLY SIGNIFICANT TOPLINE RESULTS

HEIDELBERG, Germany, and CAMBRIDGE, Mass., Dec. 16, 2021 /PRNewswire/ -- Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today provided a development update on the phase 3 trial of SHR8058 eye drops ...

2021-12-16 15:00 2725

French Neurosurgeon and Physicist Dr. Alim Louis Benabid, Recipient of 42nd Honda Prize, Honored at Online Award Ceremony

TOKYO, Dec. 16, 2021 /PRNewswire/ -- The Honda Foundation, based in Tokyo, is pleased to announce that the 42nd Honda Prize Award Ceremony was held on Wednesday, November 17, 2021, and awarded this year's prize to Dr. Alim Louis Benabid, emeritus professor at the Joseph Fourier University and chai...

2021-12-16 15:00 1938
1 ... 312313314315316317318 ... 344